Wire flash
139 institutions join Guoxin Health's earnings call, with China Southern Fund sending 20 attendees
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
Guoxin Health (000503) held a performance briefing via conference call on September 22, attracting 139 institutions including E Fund, China Asset Management, and Southern Fund, which sent 20 participants. The company reported that its health services revenue grew rapidly in the first half of 2026, driven by chronic disease management and health management business expansion. Guoxin Health noted it is integrating AI technology with health service scenarios to improve efficiency and user experience. The company highlighted a strong seasonal pattern, with Q4 revenue averaging 52.6% of annual total over the past five years. For the first half of 2026, revenue was 102 million yuan (up 6.3% YoY) while net loss attributable to shareholders was 102 million yuan (narrowing 3.21% YoY). The stock has fallen 23.87% year-to-date, with a market cap of 66.2 billion yuan. The company plans to stabilize its traditional business and develop innovative high-margin services to improve profitability.
Source report
139 institutions participated in the company's earnings call, with China Southern Fund sending 20 representatives.
Despite a shortened trading week due to the Mid-Autumn Festival (September 21–25), institutional research activity remained robust. According to Wind Information, 427 A-share listed companies were surveyed by institutions this week. Among them, Gsin Healthcare (000503) attracted the highest number of participating institutions—139—making it the only company with over 100 institutional attendees.
Other notable companies included:
- GJ Machine Tool (002046) and Xinghui Precision (300464): Over 40 institutions each.
- SF Diamond (300179) and Espressif Systems (688018): Over 30 institutions each.
Details of the Earnings Call
According to the investor relations activity record, Gsin Healthcare held its earnings briefing via a conference call on September 22. A total of 139 institutions participated, including public funds, private equity firms, securities companies, insurance firms, and bank wealth management subsidiaries. Notable participants included:
- Public funds: E Fund Management, China Asset Management, China Southern Fund, Ruiyuan Fund
- Private equity: Gaoyi Asset Management, Juming Investment
Notably, many institutions sent multiple representatives. China Southern Fund had the largest delegation with 20 participants. Several fund managers also attended, including:
- Yang Zongchang (E Fund)
- Gao Xiang and Zhu Yi (China Asset Management)
- Sun Lumin and Zhang Yanmin (China Southern Fund)
- Shen Aiqian (Ping An Fund)
- Qiu Jie (First Seafront Fund)
Fund Holdings and Business Outlook
Despite the high level of institutional interest, fund holdings data as of the end of June showed that few actively managed equity funds held Gsin Healthcare shares, with most positions concentrated in index funds.
Regarding the company's fast-growing health services business in the first half of the year, Gsin Healthcare attributed the revenue growth to the continued rollout of chronic disease management and health management services. The company stated:
"In the health services sector, leveraging our long-term accumulation in the medical, pharmaceutical, and insurance fields, we are continuously improving our chronic disease management service system, strengthening supply assurance, platform support, and intelligent service capabilities. We are actively integrating AI technology with health service scenarios to enhance service efficiency and user experience."
The company noted that its chronic disease management business in the Shandong region continues to advance, and it will focus on refining operations and improving service capabilities in existing projects.
Looking ahead, Gsin Healthcare said it will:
- Pursue steady operations
- Promote the integration of AI and other new technologies with health services
- Actively explore a "platform + data"-driven new model for health services
- Cultivate new growth drivers for long-term business development
Revenue Seasonality and Path to Profitability
Addressing the seasonal nature of its revenue and the key to narrowing or reversing non-recurring losses, Gsin Healthcare noted:
"Historically, our business shows clear seasonality, with the majority of revenue concentrated in the fourth quarter. Over the past five years, Q4 revenue has accounted for an average of 52.6% of full-year revenue."
The company outlined two key priorities moving forward:
- Strengthen the traditional business base to improve both revenue scale and quality.
- Accelerate the expansion of innovative businesses to cultivate high-margin growth points.
By improving efficiency and quality in traditional operations while driving volume growth in new businesses, Gsin Healthcare aims to create a "second growth curve", steadily improve non-recurring net profit, and enhance overall profitability and operational efficiency.
Financial Performance and Market Data
In the first half of 2026, Gsin Healthcare reported:
- Revenue: RMB 102 million, up 6.3% year-on-year
- Net profit attributable to shareholders: Loss of RMB 102 million, narrowing by 3.21% year-on-year
The company's stock price has fallen 23.87% year-to-date, with a current total market capitalization of RMB 6.62 billion.
Source
同花顺财经Neutral / independent
Part of this Story
Guoxin Health draws 139 institutions for earnings call; AI integration in health services highlighted